Research

Hormonal

Discontinuation or interruption of GLP-1 agonist therapy (semaglutide) leads to rapid weight regain and loss of cardiometabolic benefits, with patients regaining approximately two-thirds of lost weight within one year.

If you stop taking semaglutide, you will likely regain about two-thirds of the weight you lost and lose the heart and blood sugar benefits within a year. The drug works only as long as you take it. If you face a supply shortage or side effects, do not just stop; contact your provider immediately to switch to an alternative or manage the transition, as stopping leads to rapid regain.

ModerateSupportsMEDIUM confidence
However, discontinuation of AODs is associated with weight regain. For instance, patients discontinuing semaglutide regained two-thirds of their lost weight and concurrently forfeited cardiometabolic improvement one-year post discontinuation
Idan Roth et al. · Digital Health · 2025

Why this rating

Based on cited retrospective cohort studies and trial extensions (Ref 4, 8), but the pilot study itself is observational and small (n=11).

Source

The use of an automatic remote weight management system to track treatment response, identified drugs supply shortage and its consequences: A pilot study

Idan Roth et al. · Digital Health · 2025

DOI 10.1177/20552076251314090

case_series · n=11Cited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →